# Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

> **NCT01195779** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 4 (actual)

## Conditions studied

- Influenza
- Influenza Vaccines

## Interventions

- **BIOLOGICAL:** GSK Bio's influenza vaccine GSK2584786A, different formulations
- **BIOLOGICAL:** GSK Bio's influenza vaccine GSK2321138A
- **BIOLOGICAL:** Fluarix™

## Key facts

- **NCT ID:** NCT01195779
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09-30
- **Primary completion:** 2011-03-22
- **Final completion:** 2011-03-22
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.
- **Last updated:** 2020-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01195779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01195779, "Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01195779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*